Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

THRV 1268

Next Previous
Drug Profile

THRV 1268

Alternative Names: LQT-1268; THRV-1268

Latest Information Update: 20 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LQT Therapeutics
  • Developer Thryv Therapeutics
  • Class Antiarrhythmics; Heart failure therapies; Small molecules
  • Mechanism of Action Serum-glucocorticoid regulated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Long QT syndrome
  • Phase I Heart failure; Paroxysmal atrial fibrillation

Most Recent Events

  • 12 May 2026 Thryv Therapeutics announces intention to submit NDA in 2028
  • 22 Apr 2026 THRV 1268 receives Fast Track designation for Long QT syndrome [PO,Tablet] in USA
  • 14 Jan 2026 Phase-II/III clinical trials in Long QT syndrome in USA (PO) (NCT07277582)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top